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Abstract
Aims/hypothesis The aim of this work was to investigate the
relationship between use of certain insulins and risk for cancer,
when addressing the limitations and biases involved in previ-
ous studies.
Methods National Health Registries from Denmark
(1996–2010), Finland (1996–2011), Norway (2005–2010)
and Sweden (2007–2012) and the UK Clinical Practice
Research Datalink database (1987–2013) were used to conduct
a cohort study on new insulin users (N = 327,112). By using a
common data model and semi-aggregate approach, we pooled
individual-level records from five cohorts and applied Poisson
regression models. For each of ten cancer sites studied, we
estimated the rate ratios (RRs) by duration (≤0.5, 0.5–1, 1–2,
2–3, 3–4, 4–5, 5–6 and >6 years) of cumulative exposure to
insulin glargine or insulin detemir relative to that of human
insulin.
Results A total of 21,390 cancer cases occurred during a mean
follow-up of 4.6 years. No trend with cumulative treatment
time for insulin glargine relative to human insulin was observed
in risk for any of the ten studied cancer types. Of the 136
associations tested in the main analysis, only a few increased
and decreased risks were found: among women, a higher risk
was observed for colorectal (RR 1.54, 95% CI 1.06, 2.25) and
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endometrial cancer (RR 1.78, 95%CI 1.07, 2.94) for ≤0.5 years
of treatment and for malignant melanoma for 2–3 years (RR
1.92, 95%CI 1.02, 3.61) and 4–5 years (RR 3.55, 95%CI 1.68,
7.47]); among men, a lower risk was observed for pancreatic
cancer for 2–3 years (RR 0.34, 95%CI 0.17, 0.66) and for liver
cancer for 3–4 years (RR 0.36, 95%CI 0.14, 0.94) and >6 years
(RR 0.22, 95% CI 0.05, 0.92). Comparisons of insulin detemir
with human insulin also showed no consistent differences.
Conclusions/interpretation The present multi-country study
found no evidence of consistent differences in risk for ten
cancers for insulin glargine or insulin detemir use compared
with human insulin, at follow-up exceeding 5 years.
Keywords Cancer risk .Cohort study .Commondatamodel .
Cumulative treatment time . Detemir . Glargine . Human
insulin . Insulinanalogues .Newinsulinuser .Poissonmodel .
Rate ratio . Semi-aggregate . Site-specific
Abbreviations
ATC Anatomical Therapeutic Chemical
CARING Cancer risk and insulin analogues
CPRD Clinical Practice Research Datalink
DDD Defined daily dose
HRT Hormone replacement treatment
NIAD Non-insulin antidiabetic drug
NSAID Nonsteroidal anti-inflammatory drug
RR Rate ratio
Introduction
Diabetes mellitus and cancer are common diseases with rising
incidence and prevalence globally [1, 2]. Diabetes is associat-
ed with an increased risk for certain cancers [3] and the pattern
and magnitude of the excess risk are generally similar for type
1 and 2 diabetes [4, 5]. It has been suggested that certain
diabetes risk factors, as well as glucose-lowering medications,
may contribute to this association [6]. In 2009, the publication
of four observational studies [7–10] sparked concerns about
insulin glargine as a potential modifier of cancer risk [11].
The oncogenic potential of various insulin analogues has
been suggested by preclinical safety evaluations showing that
IGF and insulin receptor signalling pathways, which are es-
sential for mitogenic potency, are affected by ligand-specific
receptor dynamics, depending on the cell type [12]. Initial
observational studies [7–10] were criticised for limitations
and biases [11, 13, 14] such as short follow-up, inclusion of
prevalent insulin users and time-lag bias [15]. Further attempts
to rule out or confirm the association yielded inconsistent
findings, emphasising the importance of properly designed
and conducted observational studies [16].
The evidence from the observational studies remains incon-
sistent [17, 18], particularly due to the involvement of method-
ological drawbacks, such as time-related biases and selection
bias [15].Moreover, the findings from studies that ignore dose–
effect aspects, time-varying character of exposure, site-specific
risks or long latency of cancer are limited in their biological
plausibility [16, 19]. It was thought that RCTs, the gold stan-
dard of treatment comparisons, would disentangle the associa-
tion. However, the ORIGIN trial, which showed a null effect
[20] and constitutes perhaps the strongest RCT evidence
concerning the use of insulin analogues and cancer outcomes,
has been criticised for evaluation of cancer risk with respect to
the initial insulin glargine allocation but not the cumulative
insulin glargine use [21]. Overall, there is little robust evidence
from observational studies or RCTs to draw firm conclusions.
The present observational study, which is a part of the
Cancer Risk and Insulin Analogues (CARING) project,
sought to investigate the effect of exposure to insulin glargine
or insulin detemir on cancer risk as compared with that of
human insulin, mitigating through study design and analytical
approaches the limitations and biases involved in the previous
studies.
Methods
Overview This cohort study on new insulin users was conduct-
ed using nationwide data from the Norwegian, Swedish,
Danish and Finnish National Health Registries, as well as data
from UK general practitioners in the Clinical Practice Research
Datalink (CPRD). Project partners obtained ethics approval
from their respective authorities. The study protocol, where
data sources and study cohorts are described in more detail,
was registered in the European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance (ENCePP)
electronic register of studies [22]. To synchronise definitions
of demographics, exposures, outcomes and confounders, a
common data model and concept dictionary were developed.
Table 1 shows the study design andmethodological approaches
to the data analysis that we implemented to mitigate different
types of selection, information and time-related biases often
inherent in the observational research [15, 23–25].
Data sources, selection and follow-up of participants
National health registries in the Nordic countries comprise
computerised records for the entire population of 26 million
people, each of whom are assigned a unique personal identi-
fication number. The cancer registries have a long tradition of
providing comparable and high-quality data with almost
100% coverage of incident cancer cases [26]. Prescription
registries, established in 1995 in Denmark and Finland, in
2004 in Norway and in 2005 in Sweden, have provided ample
data for pharmaco-epidemiological research [27]. The CPRD,
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a large computerised database established in the UK in 1987,
contains anonymised medical records, including demo-
graphics, prescriptions and cancer diagnoses, that are consid-
ered to be of good quality [28]. Currently, 4.4 million individ-
uals, 6.9% of the UK population, meet the quality criteria and
are broadly representative of the entire population with regard
to demographic characteristics [29].
Within the study period (Table 2) defined as the period of
valid data collection [22], we identified all individuals having
at least one insulin purchase (Nordic countries) or prescription
(CPRD). Nordic cohorts were linked with the registered data
on cancer, death and emigration; data for the British cohort
were compiled from information on cancer and death avail-
able from the CPRD. New insulin users, who were defined
based on a 1 year lead-in period, were included if they had no
history of cancer (except non-melanoma skin cancer) and
were aged ≥18 years on the first prescription for any insulin
(index date). Follow-up started at index date and ended at the
date of emigration (Sweden, Denmark and Norway) or trans-
fer out of the CPRD, diagnosis of any cancer (excluding non-
melanoma skin cancer), death or end of follow-up, whichever
occurred first.
Cancer outcomes, insulin treatments and potential con-
foundersWe relied on coding dictionaries, compiled accord-
ing to different coding systems (ICD-7, ICD-9 [www.
icd9data.com/2007/Volume1], ICD-10 [www.who.int/
classifications/icd/en/] and ICD-O-3 in the Nordic countries;
Read code system in the CPRD), to identify incident cancer
cases defined as the first occurrence of any cancer type [22].
Multiple cancers diagnosed on the same date were considered
as distinct site-specific endpoints. Our primary interest was in
Table 2 Baseline and follow-up characteristics of the study cohorts of new users of insulin
Characteristic Denmark
(N = 66,698)
Finland
(N = 105,945)
Norway
(N = 21,541)
Sweden
(N = 85,319)
UK (CPRD)
(N = 47,609)
Study perioda 1996–2010 1996–2011 2005–2010 2007–2012 1987–2013
Male sex, n (%) 38,292 (57) 57,691 (55) 12,053 (56) 48,931 (57) 25,589 (54)
Age years, mean (SD)b 60.1 (16.0) 61.6 (15.9) 57.3 (17.8) 64.0 (16.4) 59.3 (16.3)
Age years, n (%)b
18–30 3193 (4.8) 4481 (4.2) 1634 (7.6) 3121 (3.6) 2555 (5.4)
30–40 5075 (7.6) 7317 (6.9) 2653 (12.3) 4924 (5.8) 4540 (9.5)
40–50 8334 (12.5) 11,095 (10.5) 3088 (14.3) 8383 (9.8) 5825 (12.2)
50–60 14,432 (21.6) 22,928 (21.6) 4248 (19.7) 14,870 (17.4) 9351 (19.6)
60–70 16,306 (24.5) 25,254 (23.8) 4220 (19.6) 21,378 (25.1) 11,661 (24.5)
70–80 12,527 (18.8) 22,110 (20.9) 3194 (14.8) 17,176 (20.1) 9505 (20.0)
80+ 6831 (10.2) 12,760 (12.0) 2504 (11.6) 15,466 (18.1) 4172 (8.8)
Follow-up time, years
Mean (SD) 5.3 (3.9) 5.6 (3.9) 2.7 (1.8) 2.7 (1.8) 5.7 (4.3)
Median (interquartile range) 4.5 (1.9, 7.8) 4.7 (2.3, 8.3) 2.5 (1.1, 4.1) 2.6 (1.1, 4.1) 4.7 (1.9, 8.4)
No. of person-years/1000,
all (male sex)
331.2 (184.4) 589.1 (316.9) 57.8 (32.4) 226.6 (131.3) 265.3 (141.6)
Ever-use, n (%)c
Human insulin 54,216 (81) 68,894 (65) 17,579 (82) 48,976 (57) 23,183 (49)
Insulin glargine 7151 (11) 43,741 (41) 1447 (7) 15,138 (18) 15,374 (32)
Insulin detemir 9520 (14) 24,593 (23) 868 (4) 4367 (5) 7373 (15)
Other insulin 33,388 (50) 48,280 (46) 14,376 (67) 53,810 (63) 27,491 (58)
Baseline use, n (%)
HRTd 5187 (18) 6546 (14) 1641 (17) 6621 (18) 1530 (7)
NSAIDe 17,800 (27) 29,609 (28) 5437 (25) 16,485 (19) 8935 (18)
Any oral glucose-lowering therapy 49,569 (74) 83,935 (79) 15,051 (70) 62,522 (73) 37,239 (78)
Statin 22,948 (34) 38,493 (36) 9309 (43) 39,635 (46) 24,188 (51)
a Start of study period defined according to the start of prescription registry (Nordic countries) or start of valid data collection (CPRD)
bAge at baseline
c Ever-use of specific insulin during the follow-up
d Female sex only
e Based on prescriptions only
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ten site-specific cancers. Based on NORDCAN data (cancer
statistics from Nordic countries) [26], we selected the eight
cancer types with the highest incidence rates (ICD-10 codes):
trachea and lung (C33, C34), melanoma of skin (C43), blad-
der (C67), colorectal (C18-21), non-Hodgkin lymphoma
(C82-86, C88.4), breast (C50), endometrial (C54) and prostate
(C61). Liver (C22) and pancreatic (C25) cancers were also
included because of their strong association with diabetes.
As a secondary outcome of interest, we investigated the first
occurrence of any cancer.
Based on Anatomical Therapeutic Chemical (ATC) classi-
fication codes [30] (British National Formulation codes for the
CPRD), we identified users of human insulin (A10AC01,
A10AB01, A10AD01, A10AE01, A10AF01) and the insulin
analogues insulin glargine (A10AE04) and insulin detemir
(A10AE05). Any other insulins and analogues were consid-
ered as a single group. Prescription data form the Nordic reg-
istries included the date and amount purchased, in defined
daily doses (DDDs) [30], but no information on individual
dosage. For the CPRD cohort, we derived DDDs from the
dosage information (substance strength and amount)
contained within prescription data. We assumed a daily con-
sumption of 1 DDD per day and transformed each drug record
into a period covered by the number of DDDs.
For each insulin type of interest, we defined insulin expo-
sure time-dependently as a cumulative treatment time. After
splitting the individual follow-up period into intervals of
120 days, the exposure at the beginning of each interval was
updated. The exposure began on the date of first prescription/
purchase, after which point an individual was considered ex-
posed. Cumulative treatment time accrued until exposure
stopped and remained unchanged, unless treatment was re-
sumed (see electronic supplementary material [ESM]
Methods). We then divided cumulative treatment time into
half-year categories for the first year and 1 year categories
for longer exposure; the last categories were >6 years for the
broadly categorised exposure and 9–10 years for the finely
categorised exposure. In addition, each exposure variable in-
corporated a non-exposed category assigned to individuals
remaining unexposed to the specific insulin.
We considered only confounders available in all five
datasets [22]. In addition to age, sex and calendar time, this
included use of non-insulin glucose-lowering drugs (ATC
code A10B), statins (C10A), nonsteroidal anti-inflammatory
drugs (NSAIDs; M01A) and hormone replacement treatment
(HRT; G03), defined as at least one prescription within 1 year
before the index date. We also derived several other potential
confounders: type 1 diabetes mellitus was assigned to those
aged ≤30 years with no non-insulin glucose-lowering drug on
the index date; type 2 diabetes mellitus was assigned to those
aged ≥40 years with or without non-insulin glucose-lowering
drugs; unspecified diabetes type was assigned to the rest of the
cohort. We specified the duration of insulin-treated diabetes as
time since the index date (in 1 year intervals) and defined
menopausal status time-dependently based on cut-off of
50 years of age. Furthermore, the country of the data origin
served as a covariate.
Statistical methods The individual-level data from the five
cohorts were standardised by each research partner locally
using the common data model. We then conducted centralised
analyses by uploading the unified data to a server at Statistics
Denmark, where for each cohort we constructed the individual-
level dataset to assess insulin exposure and other variables in
exactly the same way. We employed a semi-aggregate level
approach [31] to combine the datasets, which were tabulated
by cancer site as the number of cancer cases and person-years
aggregated by categorical variables. To estimate the incidence
rates, we fitted multivariable Poisson regression models to the
event numbers with the natural log of person-years as an offset.
Each model included all three time-dependent insulin exposure
variables andwas adjusted for time-dependent age and duration
of insulin-treated diabetes, sex (not in the sex-stratified analysis),
baseline calendar time, use of non-insulin antidiabetic drugs
(NIADs), other co-medication (when relevant [22]) and country.
We conducted an active-comparator analysis [25], where
the drug of interest is compared with another drug commonly
used for the same indication rather than with no treatment.
Inclusion of all three insulin exposures in the same model
allowed us to calculate the rate ratios (RRs) and 95% CIs for
a particular exposure category by contrasting the incidence
rates, which were estimated for each insulin type and duration.
In the primary analyses, we examined sex- and site-specific
cancer endpoints without separating between diabetes types
and using insulin exposures with a broader category
(>6 years) for the longer cumulative treatment time. For the
secondary analyses, we performed similar evaluations without
stratifying on sex and using insulin exposures with finer
categories.
Sensitivity analysis We also performed several sensitivity
analyses. We restricted the analyses to those who met type 2
diabetes criteria to check whether the results change by diabe-
tes type (data for individuals with type 1 diabetes were limit-
ed). In Europe, marketing authorisation for the long-acting
insulin analogues insulin glargine and insulin detemir was
granted in June 2000 and June 2004, respectively [32, 33].
Coincidentally, usage of two already-approved rapid-acting
insulin analogues, insulin lispro and insulin aspart, gained
popularity in the early 2000s. To account for the changes in
the profiles of new insulin users, we excluded those entered
before 2000. By excluding the CPRD, we addressed the po-
tential of underestimating cancer incidence due to case ascer-
tainment through the CPRD only without linkage to the na-
tional cancer registration data. For breast and endometrial can-
cer, we further adjusted for menopausal status.
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We used version 3.2.2 of R (www.R-project.org) [34] to
perform all statistical analyses, the Epi package, version 1.1.
71 (https://cran.r-project.org/web/packages/Epi/index.html)
[35] to carry out exposure calculations and the forestplot
package, version 1.7 (https://cran.r-project.org/web/
packages/forestplot/index.html) [36] for the graphical output.
Results
In the five cohorts totalling 327,112 new insulin users, men
predominated and the mean age at baseline varied between 57
and 64 years (Table 2). For the combined data, the mean
follow-up time was 4.6 years (median 3.7, interquartile range
1.7–6.3). At the end of follow-up, there was 212,848, 82,851
and 46,721 ever-users of human insulin, insulin glargine and
insulin detemir, respectively. In all cohorts, human insulin
predominated in ever-use patterns. Ever-use of insulin
glargine and insulin detemir was most common in the
Finnish cohort, as was the baseline use of non-insulin glu-
cose-lowering therapy. Baseline use of other medication also
differed between the cohorts.
A total of 1.47 million person-years accumulated and
21,390 new cancer cases occurred during the follow-up.
Table 3 shows country- and sex-specific crude incidence rates
for the ten site-specific cancers and any cancer. Prostate cancer
in men and breast cancer in women showed the highest inci-
dence rates in all cohorts except the Norwegian, where pan-
creatic cancer was the most common cancer. About 32% of all
cancer cases and the majority of pancreatic cancer cases (63%)
were diagnosed during the first year of insulin treatment.
The results of the sex- and site-specific analyses showed no
systematic differences across sites and exposure categories
(Figs 1, 2 and ESM Table 1). In women, a higher risk for
colorectal (RR 1.54, 95% CI 1.06, 2.25) and endometrial
(RR 1.78, 95% CI 1.07, 2.94) cancer was observed for the
first half-year of cumulative treatment time on insulin glargine
relative to that on human insulin and a higher risk for mela-
noma of skin for 2–3 years (RR 1.92, 95% CI 1.02, 3.61) and
4–5 years (RR 3.55, 95% CI 1.68, 7.47). In men, similar
comparisons yielded a lower risk for pancreatic cancer for
2–3 years of exposure (RR 0.34, 95% CI 0.17, 0.66), and
for liver cancer for 3–4 years (RR 0.36, 95% CI 0.14, 0.94)
and >6 years (RR 0.22, 95% CI 0.05, 0.92). In addition, the
results suggested an increase in the risk for bladder (RR 1.41,
95% CI 0.92, 2.17) and colorectal cancer (RR 1.28, 95% CI
0.94, 1.75) in men for <0.5 years and for breast cancer for
<0.5 years (RR 1.32, 95% CI 0.98, 1.79) and 0.5–1 years
(RR1.32, 95% CI 0.95, 1.85) in women.
In similar analyses performed using the 1 year categories
for longer duration of exposure (≥6 years) and both sexes
combined (not sex-specific cancers), results remained similar
(ESM Fig. 1): RR (95% CI) 1.41 (1.11, 1.79) for colorectal
cancer for <0.5 year, 0.67 (0.43, 1.03) for pancreatic cancer
for 2–3 years, 0.44 (0.21, 0.91) for liver cancer for 3–4 years
and 1.60 (1.05, 2.43) for melanoma of the skin for 4–5 years
of insulin glargine vs human insulin use. Comparisons of
insulin detemir vs human insulin and insulin glargine vs
insulin detemir also showed no consistent differences in sex-
and site-specific incidence rates (ESM Table 1) as well as in
the analyses combining both sexes (ESM Figs 2 and 3).
For any cancer in women, we found an elevated risk for
0.5 year of insulin glargine use relative to human insulin (RR
1.17, 95% CI 1.03, 1.32); in men, there was a lower risk for
0.5–1 year (RR 0.87, 95% CI 0.77, 1.00), 1–2 years (RR 0.84,
95%CI 0.73, 0.95) and >6 years (RR 0.61, 95%CI 0.48, 0.78)
of exposure (Figs 1, 2 and ESM Table 1). Analysis performed
without stratifying on sex (Fig. 3) yielded an elevated risk for
any cancer for insulin glargine use relative to human insulin
for 0.5 year (RR 1.12, 95% CI 1.03, 1.20) and a lower risk for
1–2 years (RR 0.90, 95% CI 0.83, 0.98), 6–7 years (RR 0.72,
95% CI 0.56, 0.91) and 7–8 years (RR 0.62, 95% CI 0.44,
0.86). Other analyses yielded a lower risk for any cancer in
men for 0.5–1, 2–3 and >6 years of insulin detemir use relative
to that of human insulin (ESM Table 1), and an increased risk
in men and women combined (RR 1.18, 95% CI 1.05, 1.33)
for <0.5 years of insulin glargine use relative to that of insulin
detemir (Fig. 3).
Results were robust across a range of sensitivity analyses
(ESM Tables 2, 3). Inclusion of the population with type 2
diabetes (1.31 million person-years [90%], 21,151cancer
cases [99%]) yielded similar results to those of the primary
analysis. The results did not change after either restriction of
the study period to the time after insulin glargine’s launch
(1.12 million person-years [77%], 16,838 cancer cases
[79%]) or restriction of the study population to the Nordic
cohorts. For breast and endometrial cancers, the results
remained unchanged after further adjustment for menopausal
status.
Discussion
In the cohort study of 327,112 new insulin users from five
European countries, we addressed the relationship between
insulin use and cancer incidence of ten site-specific cancers
and any cancer, when mitigating methodological shortcom-
ings and biases involved in previous studies. Comparisons
of cancer incidence by cumulative treatment time using active
comparators showed no consistent differences in the cancer
risk for insulin glargine or insulin detemir use relative to that
of human insulin use. Although we observed increased and
decreased cancer risks for some sites and treatment durations,
no trends in the risk with duration of use were seen.
The findings of previous observational studies on the rela-
tionship between cancer risk and use of insulin glargine are
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conflicting and may involve methodological limitations and
biases [15, 17]. Most of the current evidence is based on short
follow-up and use of an elementary representation of expo-
sure, ignoring the dose or duration of insulin exposure. The
latter may result in the inadequate risk estimates, especially
when treatment durations of widely differing lengths are con-
sidered equivalent [15, 19]. Of the recent studies with a short
follow-up as a main limitation [15], only four were built on a
new-user cohort [37–40], and two assessed cancer risk by
treatment durations using an active-comparator approach
[37, 38].
In the observational study on new users of insulin glargine
(n = 43,306) and human insulin (n = 9147) enrolled in a US
health plan, no association with the risk for prostate, breast,
colon and any cancer was found for treatment durations of 0–
6, 6–12, 12–24 or ≥24 months [38]. However, the risk esti-
mates reported in this study were imprecise due to the small
reference group. An observational study on a cohort of 70,027
new insulin users in France found no differences in risk at
median follow-up <3 years for bladder, breast, colorectal,
head and neck, liver, lung and kidney cancer between new
users of insulin glargine and other basal insulins, when
excluding the first year of use and defining exposure as
ever-use or cumulative dose [40]. A study of a cohort of
19,337 incident insulin users from the Netherlands found a
decreased risk for overall and colon cancer but no difference
in risk for bladder, respiratory tract and prostate cancer, when
comparing time-dependently defined cumulative time using
insulin glargine to that using human insulin, though without
further distinction between different treatment durations [39].
In the present study, we found that 22–63% of cancer cases
were diagnosed within the first year after starting insulin treat-
ment. Exclusion of 0.5–1 year of insulin use, or analysis of
short-term use only, may preclude observing the actual dynam-
ics of cancer incidence among insulin users and thus may hin-
der a better understanding of the nature of the link between
diabetes and cancer. For the first half-year of cumulative treat-
ment time on insulin glargine relative to that on human insulin,
we found an increased risk for colorectal and any cancer in
women and both sexes combined, and for endometrial cancer
in women. These findings suggest possible involvement of
detection or protopathic bias [41]. The latter is more likely to
Fig. 1 RR (adjusted for age,
calendar time, NIADs, duration of
insulin-treated diabetes, country;
for liver and colorectal cancers,
additional adjustment for relevant
co-medications) with 95% CI for
site-specific cancers and any
cancer in men by cumulative
treatment time (years) on insulin
glargine vs human insulin
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affect the present study, wherein use of insulin glargine was less
common than that of human insulin and initiation of insulin
glargine was often preceded by use of other insulins, predom-
inantly human insulin. According to the current guidelines,
switching from human insulin to insulin glargine should be
considered if an individual has hypoglycaemia or fails to reach
the target glucose level [42]. Poor glycaemic control may be a
sign of underlying cancer and thus switching insulins because
of highly variable blood glucose could be associated with more
frequently detected cancer.
Although the results of the present study suggest a shift
towards increased risk for breast cancer for the initial year of
insulin glargine vs human insulin use, no differences were
found for longer durations of treatment, when using appropri-
ate comparators and adjusting for the overall time on insulin.
In contrast to our study, three recent studies found an associ-
ation between use of insulin glargine and increased risk for
breast cancer [37, 39, 43]. However, those findings may re-
flect an imbalance in comparator and exposure characteristics
rather than differences in cancer risk due to insulin use itself.
A study on the UK’s General Practice Research Database
cohort revealed an elevated risk for >5 years since the start
of insulin glargine, when comparing insulin glargine users
with previous use of insulin vs prevalent users of other insu-
lins, matched on prior insulin duration at baseline [37].
Comparison by time since start of insulin glargine use is likely
to provide an unbiased estimate for short-term use but not for
longer use where the actual time on insulin and time since the
initiation may differ noticeably between comparators. A study
from the Netherlands reported an elevated risk for breast can-
cer when using cumulative durations without differentiation
between them, thus ignoring an imbalance between compara-
tors in the follow-up times (median of 2.2 years for insulin
glargine users and 3.8 years for human insulin users) [39]. A
recent study on a cohort of 12,468 new insulin users from the
UK’s CPRD also reported an increased risk for breast cancer
among new users of insulin glargine with extensive past ex-
posure to other insulins, when comparing insulin glargine use
of >3 years with ever-use of other insulins [43]. Comparison
of specific duration with ever-use may yield a biased result,
especially when the time period covered by specific duration
differs considerably from the period covered by ever-use.
Fig. 2 RR (adjusted for age,
calendar time, NIADs, duration of
insulin-treated diabetes, country;
for liver, colorectal, breast and
endometrial cancers, additional
adjustment for relevant
co-medications) with 95% CI for
site-specific cancers and any
cancer in women by cumulative
treatment time (years) on insulin
glargine vs human insulin
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When comparing longer cumulative treatment time on in-
sulin glargine with time on human insulin, we found a de-
creased risk for some cancers and treatment durations.
However, the results for the other exposure categories showed
no persistent differences even though an association between
the increased cancer risk and use of insulin glargine would
have been expected for the hypothesised effect. One possible
explanation is that the better glycaemic control associatedwith
use of insulin glargine, rather than human insulin [44], may
play a part. So far, the evidence from epidemiological studies
on the link between cancer risk and hyperglycaemia has been
conflicting [45–48]. Similarly, increased site-specific cancer
risks among individuals with type 1 and 2 diabetes, though
showing a smaller excess risk for type 1 diabetes, suggest that
a common diabetes-related determinant other than insulin use
affects the cancer incidence [5]. Thus, to enhance knowledge
on the interplay between diabetes and cancer, future research
should focus on the effect of long-term glycaemic control
itself, rather than different diabetes treatments.
This study has several strengths. To our knowledge, the
present study is the first to employ a semi-aggregate level
analysis across multiple populations from different countries
to compare the effect of different insulin treatments on cancer
risk. A semi-aggregate approach allowed us to analyse the
study cohorts together using uniform methods. The size of
the resulting cohort was fivefold that of the largest new-user
cohort previously studied [40]. Our study had enough statisti-
cal power for the assessment of both sex- and site-specific
cancer outcomes by cumulative durations; this assessment is
considered by Renehan [16] to be an essential feature of an
appropriately conducted pharmaco-epidemiological study on
the link between insulin analogues and cancer risk.
Through the study design and analytical stages, we ad-
dressed important limitations and mitigated typical biases
Fig. 3 RR (adjusted for age,
calendar time, sex, NIADs,
duration of insulin-treated
diabetes, country) with 95% CI
for any cancer: pairwise
comparisons of insulin glargine,
insulin detemir and human insulin
by the cumulative treatment time
(years)
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(Table 1) [15, 16, 24, 25, 49]. We adopted several other char-
acteristics proposed byRenehan [16], including cohort design,
use of validated data sources, exclusion of prevalent users and
time-dependent definition of exposure. Moreover, we used an
active-comparator design, which together with new-user de-
sign effectively reduces time-related biases and residual con-
founding [15, 25]. In addition, rather than censoring at
switching or stopping an insulin, we followed diabetic indi-
viduals through the entire insulin prescribing span. The ad-
vantages listed above, along with use of nationwide (Nordic
countries) and representative population-based (CPRD) co-
horts, provide generalisable findings that can be directly ap-
plied to real-word decision making.
Our study does, however, have some limitations, including
lack of information on important risk factors such as smoking,
BMI, sedentary lifestyle, family history of cancer and diabetes
duration, type, severity and comorbidities. Diabetes duration
has been associated with changes in cancer risk [4, 49] and
obesity was found to contribute to the increased risk of colo-
rectal cancer among individuals with type 2 diabetes [50].
Studies comparing insulin glargine users with human insulin
users found little evidence of confounding by diabetes dura-
tion, hospitalisations or cancer screening [40], or by BMI,
smoking, income or HbA1c levels [38, 43, 51]. In addition to
the use of active comparators, which reduces residual con-
founding, we accounted for the duration of insulin-treated
diabetes, which could be an effect modifier of the relationship
between insulin glargine use and cancer risk [37, 43], and
adjusted for baseline use of non-insulin glucose-lowering ther-
apy which can be considered as a proxy for one’s diabetes
stage when starting insulin treatment. We also performed sen-
sitivity analyses to evaluate the effect of diabetes type.
Other disadvantages include lack of information on insulin
dosage and the fact that exposure to non-insulin glucose-low-
ering therapy was defined as baseline usage without distinc-
tion between different therapies. Although we accounted for
country-specific characteristics, we could not rule out any po-
tential confounding effects resulting from the differences in
insulin user profiles between the countries. In addition, exam-
ining numerous potential associations is likely to produce
some false-positive results.
To summarise, the present multi-country study addressed
the clinically important question of whether some of the com-
monly used insulin treatments should be preferred over others
as being safer with respect to cancer risk. We found no persis-
tent differences in the risk for ten specific cancers and any
cancer, when comparing use of the insulin analogues insulin
glargine or insulin detemir vs human insulin. These results
add to the conclusive evidence on the absence of a relationship
between cancer incidence and use of insulin analogues at
follow-up exceeding 5 years. We see no indications to warrant
withholding of the use of the insulin analogues insulin
glargine and insulin detemir.
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